To: paper man who wrote (468 ) 6/17/1998 4:05:00 PM From: DAN LITTLE Read Replies (1) | Respond to of 4891
Paper man, Cell looks like a good possibility but not why I picked the 25th. Dr. Hirschman, in my opinion, made a mistake by sitting on his hands for over a year where share value is concerned. At least one quarter of the options should be exercised before getting the go ahead from the FDA. This will ensure enough money to get the ball rolling. I feel that Dr. Hirschman must have thought that, when the right time came, he could let out a few news releases and BINGO the share value will rise and the options will be exercised (WRONG). He extends the NCI study 3/24 then announces a phase 3 IND for Argentina 3/31 followed immediately by an open house 4/7 then the announcement of the abstract being publicized. Well it did drive the price up some but I doubt its what he expected. So here he is, probably didn't have a whole lot of market experience in the past, he's getting an education now. I would hope that he, by now, realizes that sales or the promise of sales along with some other great news (new IND issued)is what will raise the price of this stock. Remember that the options have been extended to Oct. 1. The price per share will have to come up soon and be maintained at higher levels for those options to be exersized. Dr. Hirschman will have to pull a rabbit out of his hat soon. My guess is that we will see comments on the Argentina HPV final results and DCT putting together an order. What else do we have that isn't already outdated? Mexico, China, Patents, Arthritus probably several other things that we have been keped uninformed of. But, my guess is DCT on the 25th. Thats my whole story, Dan